The rise of Sildenafil initially sparked a surge for pharma, however recent changes present a complicated picture for shareholders. Generic versions are reducing earnings, and persistent patent challenges add https://theresannqq343845.prublogger.com/40051418/the-blue-pill-and-big-pharma-a-risky-bet